MedPath

Harvard University

Harvard University logo
🇺🇸United States
Ownership
Private
Established
1636-09-08
Employees
10K
Market Cap
-
Website
http://www.harvard.edu

Clinical Trials

52

Active:1
Completed:32

Trial Phases

3 Phases

Phase 2:2
Phase 3:2
Not Applicable:47

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (51 trials with phase data)• Click on a phase to view related trials

Not Applicable
47 (92.2%)
Phase 2
2 (3.9%)
Phase 3
2 (3.9%)

Testing the Effects of Project Calm in Ukrainian Schools

Not Applicable
Completed
Conditions
Anxiety
Depression
Trauma
Child Behavior
First Posted Date
2024-01-22
Last Posted Date
2024-08-13
Lead Sponsor
Harvard University
Target Recruit Count
728
Registration Number
NCT06217705
Locations
🇺🇸

Harvard University, Cambridge, Massachusetts, United States

Brief Interventions on Social Media to Reduce Suicide Risk (Intervention 3)

Not Applicable
Terminated
Conditions
Distress, Emotional
Suicide
First Posted Date
2023-11-02
Last Posted Date
2025-08-13
Lead Sponsor
Harvard University
Target Recruit Count
29
Registration Number
NCT06114849
Locations
🇺🇸

RallyPoint Networks, Inc, Boston, Massachusetts, United States

Brief Interventions on Social Media to Reduce Suicide Risk (Intervention 1)

Not Applicable
Terminated
Conditions
Suicide
Distress, Emotional
First Posted Date
2023-11-02
Last Posted Date
2025-08-13
Lead Sponsor
Harvard University
Target Recruit Count
942
Registration Number
NCT06114875
Locations
🇺🇸

RallyPoint Networks, Inc, Boston, Massachusetts, United States

Brief Interventions on Social Media to Reduce Suicide Risk (Intervention 2)

Not Applicable
Withdrawn
Conditions
Mental Health Issue
Stigma, Social
First Posted Date
2023-11-02
Last Posted Date
2025-08-13
Lead Sponsor
Harvard University
Target Recruit Count
10000
Registration Number
NCT06114862
Locations
🇺🇸

RallyPoint Networks, Inc, Boston, Massachusetts, United States

The Ukrainian Student Problem Solving Project

Not Applicable
Completed
Conditions
Trauma
Anxiety
Child Behavior
Depression
First Posted Date
2023-10-03
Last Posted Date
2024-08-13
Lead Sponsor
Harvard University
Target Recruit Count
778
Registration Number
NCT06064578
Locations
🇺🇸

Harvard University, Cambridge, Massachusetts, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 10
  • Next

News

Patient-Derived Esophageal Cancer Organ Chips Accurately Predict Chemotherapy Response in Clinical Study

Researchers developed patient-specific esophageal adenocarcinoma organ chips that accurately predicted chemotherapy responses in all eight patients tested, overcoming limitations of traditional organoid models.

XtalPi Secures $100 Million Partnership with Harvard's Gregory Verdine to Advance AI-Driven Drug Discovery

XtalPi has signed a Letter of Intent with DoveTree LLC, founded by Harvard Professor Gregory Verdine, for a collaboration worth $100 million upfront plus potential milestone payments exceeding $10 billion.

Catalyst Pharmaceuticals Appoints Dr. William Andrews as Chief Medical Officer to Lead Rare Disease Strategy

Catalyst Pharmaceuticals appointed Dr. William T. Andrews as Chief Medical Officer, succeeding retiring Dr. Gary Ingenito after his successful 10-year tenure with the company.

Brooklyn Health Raises $6.5M to Transform CNS Clinical Trial Measurement with AI-Powered Platform

Brooklyn Health secured $6.5 million in seed funding led by HealthX Ventures to advance its AI-powered clinical trial measurement technology for central nervous system disorders.

Federal Circuit Remands CRISPR Patent Dispute to PTAB in Ongoing Editas Medicine Case

The U.S. Court of Appeals for the Federal Circuit has partially vacated the Patent Trial and Appeal Board's previous decision in the CRISPR/Cas9 patent interference case, remanding it for further review.

Trump Administration's Clinical Trial System Shutdown Shocks Medical Research Community

The Trump administration issued an unexpected "stop work order" for SMART IRB, a critical system that streamlines multisite clinical trials, leaving researchers across the country baffled.

Vizgen Settles Litigation with 10x Genomics and Harvard, Secures Future for MERFISH Technology

• Vizgen has reached a settlement agreement with 10x Genomics and Harvard University, ending litigation in both U.S. and European courts after three days of trial in Delaware. • The resolution secures Vizgen's freedom to operate its MERFISH technology, allowing the company to continue building its intellectual property portfolio in spatial biology without legal impediments. • Since introducing MERSCOPE in 2021, Vizgen's technology has been featured in over 300 scientific publications spanning neurodegenerative disease, oncology, and other research fields.

Artis BioSolutions Launches with Landmark Bio Acquisition to Transform Advanced Therapy Manufacturing

Artis BioSolutions has emerged from stealth mode with the strategic acquisition of Landmark Bio, positioning itself as a premier CDMO for advanced genetic medicine development.

Harvard-Licensed Antibiotic Platform Launches as Kinvard Bio to Combat Drug-Resistant Infections

Kineticos Life Sciences launches Kinvard Bio to develop novel oxepanoprolinamide antibiotics, licensed from Harvard University's Myers Lab, targeting multi-drug resistant bacterial infections.

Apple Launches Research App with Three Major Health Studies Focusing on Women's Health, Heart Disease, and Hearing

Apple has introduced its Research app in the US, enabling iPhone and Watch users to participate in studies on women's health, cardiovascular conditions, and hearing impacts, with leading research institutions.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.